IL5 and airway hyperresponsiveness: Treatments with kaempferol attenuated the Th2-driven allergic airway disease in an experimental model of asthma by decreasing production of IL-5 and IL-13 and amelioration of airway hyperresponsiveness (AHR) induced by OVA challenge.